Results 191 to 200 of about 150,000 (304)

Microbiota evaluation in acute appendicitis: a preliminary study of appendix and childhood oral microbiota. [PDF]

Front Oral Health
Katzenelson RT, Izzo P, Corrallo BR, Crescente CL, Alcantara AC, de Carvalho FG, Marques LS, de Sousa ET, Parisotto TM.   +8 more
europepmc   +1 more source

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This review synthesises current knowledge on gut microbiome involvement in obesity and hypertension, evaluates microbiome‐based therapeutic strategies, and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics.
Andrej Belančić, Almir Fajkić, Yusuf Ziya Sener, Ana Jelaković, Lejla Alić, Elvira Meni Maria Gkrinia, Donatella Verbanac, Bojan Jelaković   +7 more
wiley   +1 more source

Why the COPD Microbiome Matters: How Airway Microbes Shape Disease Severity and Treatment Response. [PDF]

Int J Chron Obstruct Pulmon Dis
Jia S, Liu P, Zhang H, Zeng H, Chen G, Zhao L.   +5 more
europepmc   +1 more source

A Bifunctional Protease Cleaves the Leader Peptide in the Biosynthesis of Class I Microviridins

ChemBioChem, Volume 27, Issue 7, 14 April 2026.
Biochemical characterization of the peptidase candidate NosP reveals bifunctional endo‐ and aminopeptidase activity in the leader peptide removal of class I microviridins from Nostoc punctiforme. The discovery of the first leader‐processing peptidase from microviridin biosynthesis may pave the way for the efficient production and bioengineering of ...
Nico Brüssow, Stella Scholz, Antje Stindt, Vincent Wiebach, Tino Damaszek, Roderich D. Süssmuth, Elke Dittmann, Martin Baunach   +7 more
wiley   +1 more source

Comparative analysis of stress markers, metabolic health, and gut microbiota in healthy and disabled dogs in long-term shelters in Thailand. [PDF]

PLoS One
Saengthong A, Brown JL, Towiboon P, Punturee K, Buddhasiri S, Nganvongpanit K, Punyapornwithaya V, Tocharoennirattisai W, Khonmee J.   +8 more
europepmc   +1 more source

Neuroprotective Effects of Time‐Restricted Feeding Combined With Different Protein Sources in MPTP‐Induced Parkinson's Disease Mice Model and Its Modulatory Impact on Gut Microbiota Metabolism

Advanced Science, Volume 13, Issue 19, 2 April 2026.
Time‐restricted feeding (TRF) exerts protein‐dependent neuroprotective effects in an MPTP‐induced Parkinson's disease model. In casein‐fed mice, TRF improves gut barrier integrity and reduces neuroinflammation, possibly via modulation of Allobaculum and BCAAs.
Ting Li, Jian Wu, Sheng‐Yang Zhou, Ming‐An Li, Li‐Ping Zhao, Ao Wang, Yi‐Zhi Song, Wen‐Yan Huang, Lu‐Lu Tan, Chen‐Meng Qiao, Wei‐Jiang Zhao, Chun Cui, Yan‐Qin Shen   +12 more
wiley   +1 more source

Mycotoxins, gut microbiota alterations and liver disease in animals: A scoping review. [PDF]

Cell Biol Toxicol
Lázaro Á, Frangiamone M, de Las Heras M, Ruiz MJ.   +3 more
europepmc   +1 more source

Effects of NaHCO3 Alkalinity Stress on Micropterus salmoides

Aquaculture, Fish and Fisheries, Volume 6, Issue 2, April 2026.
ABSTRACT To provide guidance for the actual cultivation of Micropterus salmoides in saline alkali environment, the effects of NaHCO3 alkalinity stress on enzymatic activity, tissue structure and gut microbiota were investigated. The experimental groups consisted of Group 1 (no NaHCO3 added), Group 2 (10 mmol/L NaHCO3 alkalinity) and Group 3 (30 mmol/L ...
Wen‐ping Jiang, Shun Cheng, Shi‐li Liu, Jian‐bo Zheng, Mei‐li Chi, Chao Zhu, Jun‐zhi Luo, Fei Li   +7 more
wiley   +1 more source

Gut microbiota and spleen-strengthening and dampness-dispelling therapies in obesity and related metabolic disorders: key mechanisms and therapeutic potential. [PDF]

Front Pharmacol
Peng H, Jiang J, Tan Z, Jiang P.
europepmc   +1 more source

Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment for various cancers, including advanced hepatocellular carcinoma (HCC). However, a significant proportion of patients with HCC, particularly those with metabolic dysfunction‐associated liver disease (MASLD), exhibit resistance to ICI therapy.
Mazen Elsheikh, Mohamad Ali Ibrahim, Sherry Fares, Megha Bhongade, Karim Adhem, Ximena I. Ramirez‐Morales, Ahmed O. Kaseb, Joseph Petrosino, Manal M. Hassan, Prasun K. Jalal   +9 more
wiley   +1 more source